DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製葯(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2348)

UPDATE ON JOINT VENTURE COMPANY

EARLY COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICAL TRIAL FOR EBRONUCIMAB (PCSK9 INHIBITORS) FOR TREATING PATIENTS SUFFERING FROM HIGH- OR VERY HIGH-RISK HYPERCHOLESTEROLEMIA IN THE PRC

This is a voluntary announcement made by Dawnrays Pharmaceutical (Holdings) Ltd. (the "Company" together with its subsidiaries, collectively referred to as the "Group") .

Reference is made to the announcements ("Announcements") of the Company dated 14 December 2016, 16 March 2017 and 24 June 2020 in relation to formation of the joint venture company, namely 康融東方(廣東)醫藥有限公司 (AD Pharmaceuticals Co., Ltd.) ("AD Pharmaceuticals"), between Dawnrays Biotechnology Capital (Asia) Limited ("Dawnrays Biotech"), a wholly-owned subsidiary of the Company, and 中山康方生物醫藥有限公司 (Akeso Biopharma Inc.)("Akeso Biopharma"), pursuant to the JV Agreement dated 14 December 2016. Terms defined in the Announcements shall have the same meanings when used herein unless the context requires otherwise.

AD Pharmaceuticals, a joint venture company owned as to 35% by the Group and 65% by Akeso Biopharma **(**a wholly-owned subsidiary of Akeso, Inc., a clinical-stage biopharmaceutical company committed to in-house discovery, development and commercialization of first-in-class and best-in-class therapies and whose shares are listed on the Stock Exchange (stock code: 9926)**)**, is primarily engaged in the development of Ebronucimab(PCSK9 Inhibitors; research and development code:AK102) and AK109 (a new all-human VEGFR-2 monoclonal antibody, developed by AD Pharmaceuticals).

**for identification purpose*

The Company has been informed by AD Pharmaceuticals that the enrollment of 260 patients in Phase IIb clinical trial for Ebronucimab (AK102), which is developed for treating patients suffering high- or very high-risk hypercholesterolemia (the "Indication") in the PRC has been completed ahead of schedule. Phase III clinical trial for the Indication will be conducted in the PRC. The early clinical trial results of Ebronucimab indicates that, when compared with Repatha (evolocumab) that has the same target, Ebronucimab can fully inhibits PCSK9. Ebronucimab can significantly reduce cholesterol in all patients administrated. The Company expects Ebronucimab to become the first domestically-developed PCSK9 drug in the PRC to meet the needs of a large number of cardiovascular patients.

ABOUT EBRONUCIMAB (PCSK9 INHIBITORS)

Ebronucimab (AK102) is primarily used for the treatment of primary hyperlipidemias, including homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH) and other primary hypercholesterolemia patients. When used in addition to or in the place of statin drugs, PCSK9 inhibitors (Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab)) have demonstrated efficacy in dramatically reducing cholesterol and decreasing the incidence of heart attack or stroke in patients. Ebronucimab (AK102) has the same target as evolocumab and alirocumab. According to Frost & Sullivan, Repatha (evolocumab) and Praluent (alirocumab) collectively experienced a rapid increase in global sales from US$20 million in 2015, when they were launched, to US$858 million in 2018, representing a CAGR of 250.2%.

This announcement is made on a basis to keep shareholders and potential investors informed of the latest development of the Group. There is no assurance that Ebronucimab will be successfully developed and ultimately marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board of
Dawnrays Pharmaceutical (Holdings) Limited
Li Kei Ling
Chairman

Hong Kong, 2 December 2020

As at the date of this announcement, the Board of the Company comprises three executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai and Mr. Chen Shaojun; one non-executive director, namely Mr. Leung Hong Man; three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.